Dissemin is shutting down on January 1st, 2025

Published in

American Society of Hematology, Blood, 20(119), p. 4645-4655, 2012

DOI: 10.1182/blood-2011-10-381996

Links

Tools

Export citation

Search in Google Scholar

Comprehensive analysis of unique cases with extraordinary control over HIV replication

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

True long-term nonprogressors (LTNP) / elite controllers (EC) maintain durable control over HIV replication without antiretroviral therapy. Herein we describe four unique individuals who were distinct from conventional LTNP/EC in that they had extraordinarily low HIV burdens and comparatively weak immune responses. As a group, typical LTNP/EC have unequivocally reactive HIV-1 Western blots, viral loads below the lower threshold of clinical assays, low levels of persistent viral reservoirs, an overrepresentation of protective HLA alleles and robust HIV-specific CD8(+) T-cell responses. The four unique cases were distinguished from typical LTNP/EC based on weakly reactive Western blots, undetectable plasma viremia by a single copy assay, extremely low to undetectable HIV DNA levels and difficult to isolate replication-competent virus. All four had at least one protective HLA allele and CD8(+) T-cell responses that were disproportionately high for the low antigen levels, but comparatively lower than those of typical LTNP/EC. These unique individuals exhibit extraordinary suppression over HIV replication and, therefore, higher-level control than has been demonstrated in previous studies of LTNP/EC. Additional insight into the full spectrum of immune-mediated suppression over HIV replication may enhance our understanding of the associated mechanisms, which should inform the design of efficacious HIV vaccines and immunotherapies